Press Releases

Press Releases

Date Title
November 8, 2022
UNITY Biotechnology, Inc. Reports Third Quarter 2022 Financial Results and Business Updates
- Announced positive 24-week data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection led to statistically significant and clinically meaningful improvement in BCVA with favorable safety profile through six months - - 16-Week Data from Phase 2 ENVISION Study
November 1, 2022
UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
A single injection of UBX1325 led to a statistically significant and clinically relevant improvement in Best Corrected Visual Acuity (BCVA) of 7.6 ETDRS letters at 24 weeks compared to sham treatment UBX1325 maintained stabilization of retinal structure, as measured by central subfield thickness
October 31, 2022
UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema
Program Update with retinal expert Arshad M. Khanani, M.D., M.A., FASRS, to be held on Tuesday, November 1 at 5:00 a.m. PT/8:00 a.m. ET SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY” or the “Company”) (Nasdaq:UBX), a biotechnology company
October 19, 2022
UNITY Biotechnology Announces Reverse Stock Split Effective at 5:00 PM Eastern Time Today
UBX common stock expected to begin trading on a split-adjusted basis on October 20, 2022 SOUTH SAN FRANCISCO, Calif. , Oct. 19, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY” or the “Company”) (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt or reverse
October 11, 2022
UNITY Biotechnology’s Investor and Analyst Day to Highlight UBX1325 Program in Age-Related Diseases of the Eye
- Presentations from UNITY’s leadership team and fireside chat with retina expert Robert B. Bhisitkul , M.D., Ph.D., on Wednesday, October 12 from 8:00 a.m. to 9:30 a.m. ET - SOUTH SAN FRANCISCO, Calif. , Oct. 11, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc.
October 6, 2022
UNITY Biotechnology to Host Investor and Analyst Day to Discuss Clinical Development Program for UBX1325 in Age-Related Diseases of the Eye
-Webinar to feature presentation from retinal expert Robert B. Bhisitkul , M.D., Ph.D., on Wednesday, October 12 at 5:00 a.m. PT / 8:00 a.m. ET - SOUTH SAN FRANCISCO, Calif. , Oct. 06, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics
September 19, 2022
UNITY Biotechnology Completes Enrollment in Phase 2 ENVISION Study of UBX1325 in Wet Age-related Macular Degeneration
Enrollment of 51 patients exceeds target by ~10% due to high interest in the study 16-week data anticipated in Q1 2023 and 24-week data anticipated in Q2 2023 SOUTH SAN FRANCISCO, Calif. , Sept. 19, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company
August 31, 2022
UNITY Biotechnology to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Aug. 31, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will participate in the following investor
August 17, 2022
UNITY Biotechnology Announces Pricing of Upsized Underwritten Public Offering
SOUTH SAN FRANCISCO, Calif. , Aug. 17, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced the pricing of an upsized underwritten public offering of 64,285,714 shares
August 16, 2022
UNITY Biotechnology Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. , Aug. 16, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it has commenced a proposed underwritten public offering of $25.0
Displaying 1 - 10 of 28